← Eichor
Study identifier: NCT07060274 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients

Condition: Giant Cell Arteritis (GCA) · Doppler Ultrasound  ·  Sponsor: Centre Hospitalier le Mans

PhaseNA
Planned participants64
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50. Vasculitis lesions cause thickening of the arterial wall, visible on temporal artery biopsy (TAB) or vascular imaging (echo-Doppler, angio-CT, angio-MRI, 18FDG PET-CT). This is a severe disease that can lead to blindness. Early diagnosis is essential, so that steroids therapy can be started as soon as possible to prevent complications. Doppler ultrasonography of the temporal arteries provides rapid, non-invasive diagnostic support. However, the recommendations do not specify how soon temporal artery Doppler should be performed after steroids treatment, except that the halo sign would disappear after about 5 days on steroids. Sensitivity seems to be better when the examination is performed early, but the time taken for the halo sign to disappear is unknown. The investigator suggests that the disappearance of the temporal artery halo sign in GCA patients is observed earlier than D14 of steroids treatment usually reported in the literature. He speculates that the sensitivity of the temporal artery Doppler decreases as early as D3 of steroids treatment, and that beyond D7 it is not useful to perform this examination as its sensitivity becomes too low.

This description comes directly from the study's public registry record.

Talk to the study team

Christelle JADEAU, MD, PhD  ·  +332 44 71 07 81  ·  cjadeau@ch-lemans.fr

Pierre LOZAC'H, MD  ·  +332 43 43 29 12  ·  plozach@ch-lemans.fr

Always discuss trial participation with your own doctor first.

Locations (6)

Centre Hospitalier du MansLe Mans, Sarthe, FranceRecruiting
CHU d'AngersAngers, FranceRecruiting
CHU Caen NormandieCaen, FranceNot Yet Recruiting
CHU Dijon - Hôpital François MitterrandDijon, FranceNot Yet Recruiting
Groupe hospitalier La Rochelle-Ré-AunisLa Rochelle, FranceRecruiting
CHU NantesNantes, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07060274